Non-insulin pharmacological therapies for treating type 1 diabetes

Research output: Contribution to journalReviewResearchpeer-review

Standard

Non-insulin pharmacological therapies for treating type 1 diabetes. / Frandsen, Christian Seerup; Dejgaard, Thomas Fremming; Madsbad, Sten; Holst, Jens Juul.

In: Expert Opinion on Pharmacotherapy, Vol. 19, No. 9, 2018, p. 947-960.

Research output: Contribution to journalReviewResearchpeer-review

Harvard

Frandsen, CS, Dejgaard, TF, Madsbad, S & Holst, JJ 2018, 'Non-insulin pharmacological therapies for treating type 1 diabetes', Expert Opinion on Pharmacotherapy, vol. 19, no. 9, pp. 947-960. https://doi.org/10.1080/14656566.2018.1483339

APA

Frandsen, C. S., Dejgaard, T. F., Madsbad, S., & Holst, J. J. (2018). Non-insulin pharmacological therapies for treating type 1 diabetes. Expert Opinion on Pharmacotherapy, 19(9), 947-960. https://doi.org/10.1080/14656566.2018.1483339

Vancouver

Frandsen CS, Dejgaard TF, Madsbad S, Holst JJ. Non-insulin pharmacological therapies for treating type 1 diabetes. Expert Opinion on Pharmacotherapy. 2018;19(9):947-960. https://doi.org/10.1080/14656566.2018.1483339

Author

Frandsen, Christian Seerup ; Dejgaard, Thomas Fremming ; Madsbad, Sten ; Holst, Jens Juul. / Non-insulin pharmacological therapies for treating type 1 diabetes. In: Expert Opinion on Pharmacotherapy. 2018 ; Vol. 19, No. 9. pp. 947-960.

Bibtex

@article{18d0ea783d4a4aad9cbf87dad6777cb8,
title = "Non-insulin pharmacological therapies for treating type 1 diabetes",
abstract = "Introduction: Despite intensified insulin treatment, many persons with type 1 diabetes (T1D) do not achieve glycemic and metabolic targets. Consequently, non-insulin chemical therapies that improve glycemic control and metabolic parameters without increasing the risk of adverse events (including hypoglycemia) are of interest as adjunct therapies to insulin.Areas covered: In this review, the authors discuss the efficacy and safety of non-insulin therapies, including pramlintide, glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase-4 inhibitors (DPP-4), sodium-glucose cotransporter (SGLT1 and SGLT2) inhibitors, metformin, sulfonylureas, and thiazolidinediones as add-on therapies to insulin in T1D.Expert opinion: The current evidence shows that the efficacy of non-insulin therapies as add-on therapies to insulin is minimal or modest with an average HbA1c reduction of 0.2-0.5{\%} (2-6mmol/mol). Indeed, the current focus is on the development of SGLT inhibitors as adjuncts to insulin in type 1 diabetes. Studies of subgroups with obesity, residual beta-cell function (including newly diagnosed patients) and patients prone to hypoglycemia could be areas of future research.",
keywords = "Type 1 diabetes, T1DM, T1D, pramlintide, amylin, glucagon-like peptide-1, GLP-1RA, dipeptidyl peptidase-4 inhibitor, DPP-4, sodium-glucose cotransporters, SGLT-1, SGLT-2, metformin, sulfonylurea, SU, thiazolidinediones, TZD",
author = "Frandsen, {Christian Seerup} and Dejgaard, {Thomas Fremming} and Sten Madsbad and Holst, {Jens Juul}",
year = "2018",
doi = "10.1080/14656566.2018.1483339",
language = "English",
volume = "19",
pages = "947--960",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor & Francis",
number = "9",

}

RIS

TY - JOUR

T1 - Non-insulin pharmacological therapies for treating type 1 diabetes

AU - Frandsen, Christian Seerup

AU - Dejgaard, Thomas Fremming

AU - Madsbad, Sten

AU - Holst, Jens Juul

PY - 2018

Y1 - 2018

N2 - Introduction: Despite intensified insulin treatment, many persons with type 1 diabetes (T1D) do not achieve glycemic and metabolic targets. Consequently, non-insulin chemical therapies that improve glycemic control and metabolic parameters without increasing the risk of adverse events (including hypoglycemia) are of interest as adjunct therapies to insulin.Areas covered: In this review, the authors discuss the efficacy and safety of non-insulin therapies, including pramlintide, glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase-4 inhibitors (DPP-4), sodium-glucose cotransporter (SGLT1 and SGLT2) inhibitors, metformin, sulfonylureas, and thiazolidinediones as add-on therapies to insulin in T1D.Expert opinion: The current evidence shows that the efficacy of non-insulin therapies as add-on therapies to insulin is minimal or modest with an average HbA1c reduction of 0.2-0.5% (2-6mmol/mol). Indeed, the current focus is on the development of SGLT inhibitors as adjuncts to insulin in type 1 diabetes. Studies of subgroups with obesity, residual beta-cell function (including newly diagnosed patients) and patients prone to hypoglycemia could be areas of future research.

AB - Introduction: Despite intensified insulin treatment, many persons with type 1 diabetes (T1D) do not achieve glycemic and metabolic targets. Consequently, non-insulin chemical therapies that improve glycemic control and metabolic parameters without increasing the risk of adverse events (including hypoglycemia) are of interest as adjunct therapies to insulin.Areas covered: In this review, the authors discuss the efficacy and safety of non-insulin therapies, including pramlintide, glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase-4 inhibitors (DPP-4), sodium-glucose cotransporter (SGLT1 and SGLT2) inhibitors, metformin, sulfonylureas, and thiazolidinediones as add-on therapies to insulin in T1D.Expert opinion: The current evidence shows that the efficacy of non-insulin therapies as add-on therapies to insulin is minimal or modest with an average HbA1c reduction of 0.2-0.5% (2-6mmol/mol). Indeed, the current focus is on the development of SGLT inhibitors as adjuncts to insulin in type 1 diabetes. Studies of subgroups with obesity, residual beta-cell function (including newly diagnosed patients) and patients prone to hypoglycemia could be areas of future research.

KW - Type 1 diabetes

KW - T1DM

KW - T1D

KW - pramlintide

KW - amylin

KW - glucagon-like peptide-1

KW - GLP-1RA

KW - dipeptidyl peptidase-4 inhibitor

KW - DPP-4

KW - sodium-glucose cotransporters

KW - SGLT-1

KW - SGLT-2

KW - metformin

KW - sulfonylurea

KW - SU

KW - thiazolidinediones

KW - TZD

U2 - 10.1080/14656566.2018.1483339

DO - 10.1080/14656566.2018.1483339

M3 - Review

VL - 19

SP - 947

EP - 960

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 9

ER -

ID: 213159433